Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) EBITDA (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed EBITDA for 3 consecutive years, with -$26.4 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, EBITDA fell 15.45% year-over-year to -$26.4 million, compared with a TTM value of -$126.6 million through Dec 2021, down 90.01%, and an annual FY2024 reading of -$69.6 million, up 13.66% over the prior year.
  • EBITDA was -$26.4 million for Q4 2021 at Black Diamond Therapeutics, up from -$35.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$3.8 million in Q1 2019 and bottomed at -$35.1 million in Q3 2021.
  • Average EBITDA over 3 years is -$19.0 million, with a median of -$15.8 million recorded in 2020.
  • Peak annual rise in EBITDA hit 10.35% in 2020, while the deepest fall reached 216.19% in 2020.
  • Year by year, EBITDA stood at -$9.9 million in 2019, then crashed by 131.77% to -$22.9 million in 2020, then decreased by 15.45% to -$26.4 million in 2021.
  • Business Quant data shows EBITDA for BDTX at -$26.4 million in Q4 2021, -$35.1 million in Q3 2021, and -$34.5 million in Q2 2021.